CMCarlo A. Marra

Carlo A. Marra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlo A. Marra has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quality-of-Life Assessment in an Outpatient Parenteral Antibiotic Program

    by Alan F Goodfellow, Amy O Wai, Luciana Frighetto, Carlo A Marra, Barbara M Ferreira, M Lynn Chase, Ruth E Nicol, Carole A Leong, Sally Tomlinson, Peter J Jewesson

    • 1 January 2002
      • Vol. 9  (4) , 183-9

    Patterns of use and patients' attitudes toward complementary medications: a survey of adult general medicine patients at a major Canadian teaching hospital.

    by Troy Frederick Cook, Luciana Frighetto, Carlo A Marra, Peter J Jewesson

    To characterize the preadmission and hospital utilization of, and patients' attitudes toward, complementary medications. Patient survey data were collected at an acute care hospital over a four-month period for 85 patients who had been admitted to the general medicine wards. Patient information about complementary medicine use and opinions were obtained through patient interviews. Patient demographic information including age, sex, ethnic background, level of education and annual household income were gathered. Patients were eligible to participate in the survey if they were on a general medicine ward on any given interview day. Patients were excluded if they were absent from their room, were sleeping, spoke no English and had no translator present, were occupied by other health care staff or friends and family on days of interviewing, or did not consent. Logistical regression was used to identify predictive factors for complementary medicine use. Eighty-five of 105 patients (81%) consented to complete the survey. The mean patient age was 55 years (range 19 to 91), and 45 respondents (53%) were male. About one-third of patients surveyed reported having previously visited a practitioner of natural medicine. Thirty-three patients (39%) interviewed indicated that they had used complementary medications at some time in their lives. One in six respondents (17%) reported using a complementary medicine immediately before admission to the hospital, although only two patients (3%) reported using a complementary medicine while in hospital. The most commonly reported products of use were echinacea, garlic pills and ginseng. Five patients (15%) indicated that their pharmacists were aware of their complementary medicine use, while 17 patients (52%) stated that their family doctors were aware. The majority of patients indicated they were satisfied with the information provided to them from various sources. Other data collected revealed that almost one-half would choose to take a complementary medicine for the ailment that brought them into the hospital. Univariate analysis indicated that age was a significant negative predictor for complementary medication use. The use of complementary medications on general medicine wards appears to be low; however, preadmission use of complementary medications appears common. The present study results suggest that use of complementary medications may go unreported; therefore, all health care providers should be aware of and knowledgeable about the potential self-administration of complementary medications by their patients.


  • Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

    by Shannon E. Sinclair, Luciana Frighetto, Peter S. Loewen, Rubina Sunderji, Philip Teal, Susan C. Fagan, Carlo A. Marra

    Background: There are over 40 000 ischaemic strokes annually in Canada, which result in significant morbidity, mortality and burden to the healthcare system. A recent, large clinical trial has evaluated tissue plasminogen activator (t-PA) intravenously for the treatment of acute ischaemic stroke with promising outcomes but with an increased risk of symptomatic intracranial haemorrhage. Objective: To compare clinical and economic outcomes of intravenous t-PA therapy (0.9 mg/kg, to a maximum of 90mg, initiated within 3 hours of stroke onset) versus no t-PA for acute ischaemic stroke based on the outcomes achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial. Design: A Markov model depicting the natural lifetime course after an initial acute ischaemic stroke. On the basis of this model, a simulated trial compared no t-PA with t-PA. Patients: A hypothetical cohort of 1000 patients with acute ischaemic stroke. Study perspective: Canadian healthcare system. Outcome measures: Total acute stroke and post-stroke treatment costs and cumulative quality-adjusted life-years (QALYs). Results: For a hypothetical cohort of 1000 patients, the estimated lifetime stroke costs were 103 100 000 Canadian dollars ($Can) [1999 values) in the t-PA arm ($Can103 100 per patient) compared with $Can106 900 000 in the no t-PA arm ($Can106 900 per patient), yielding a lifetime cost difference of $Can3 800 000 in favour of t-PA versus no t-PA ($Can3800 per patient). In the hypothetical cohort, t-PA treatment resulted in 13 130 QALYs versus 9670 QALYs with no t-PA treatment. This translated into a net benefit of 3460 additional QALYs per 1000 patients (3.46 QALYs per patient). No treatment, outcome or economic variables influenced the model outcome. Conclusion: From the standpoint of cost effectiveness, treatment of acute ischaemic stroke with intravenous t-PA is an economically attractive strategy.


  • Cost-effectiveness of prophylactic dolasétron or droperidolvs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery

    by Luciana Frighetto, Peter S. Loewen, John Dolman, Carlo A. Marra

    To assess the cost-effectiveness of prophylactic therapy (1.25 mg droperidol or 50 mg dolasétroniv) vs no prophylaxis (rescue therapy) for the prevention of post-operative nausea and vomiting (PONV) from a Canadian hospital perspective. Design: A predictive decision analytic model using previously published clinical and economic evaluations, and costs of medical care in Canada. Subjects: Ambulatory gynecology surgery patients,Interventions: Three strategies administered prior to emergence from anesthesia were compared: 1.25 mg droperidoliv, 50 mg dolasétroniv; and no prophylaxis (rescue therapy). The base case mean cost per patient receiving dolasétron prophylaxis was $28.08 CAN compared with $26.88 CAN per patient receiving droperidol prophylaxis, resulting in a marginal cost of $ 1.20 CAN. This difference translated in an additional cost of $ 12.00 CAN for the dolasétron strategy per adverse event avoided over the droperidol strategy. The base case mean cost per patient not receiving prophylaxis was $26.92 resulting in marginal costs of $ 1.16 CAN and $0.04 CAN when compared to dolasétron and droperidol, respectively. Compared with the no prophylaxis strategy, dolasétron prophylaxis resulted in an incremental cost-effectiveness ratio of $5.82 CAN per additional PONV-free patient. The mean costs incurred per PONV-free patient were calculated to be $48.41 for the dolasétron strategy, $46.34 for the droperidol strategy and $70.83 for the no prophylaxis strategy. Dolasetron and droperidol given intraoperatively were more cost-effective than no prophylaxis for PONV in patients undergoing ambulatory gynecologic surgery. The difference between the two agents was small and favoured droperidol. The model was robust to plausible changes through sensitivity analyses. Évaluer la rentabilité d’une thérapie prophylactique (1,25 mg de dropéridol ou 50 mg de dolasétroniv) vs aucune prophylaxie dans le but de prévenir les nausées et vomissements postopératoires (NVPO) dans le contexte d’un hôpital canadien. Devis derecherche: Un modèle analytique de décision prédictive basé sur les évaluations cliniques et économiques déjà publiées et sur le coût des soins médicaux au Canada.Sujets: Patientes de chirurgie gynécologique ambulatoire.Interventons: Trois prescriptions administrées avant le réveil ont été comparées; 1,25 mg de dropéridoliv, 50 mg dolasétroniv; et aucune prophylaxie. Le coût moyen de base par patient qui a reçu du dolasétron a été de 28,08 $ CAN comparé à 26,88 $ par patient qui a reçu du dropéridol, une différence de 1,20 $. Cette différence s’est traduite en un coût additionnel de 12,00 $ CAN, avec la thérapie au dolasétron comparée à la thérapie au dropéridol, pour chaque événement défavorable évité. Le coût de base moyen par patient sans prophylaxie était de 26,92 $ établissant une différence de 1, 16 $ et 0,04 $ comparé au dolasétron et au dropéridol, respectivement. Comparée à la stratégie de non-prophylaxie, la prophylaxie au dolasétron a entraîné une rentabilité accrue au coût de 5,82 $ par patient supplémentaire sans NVPO. Le coût moyen encouru par patient sans NVPO a été de 48,41 $ avec le dolasétron, de 46,34 $ avec le dropéridol et de 70,83 $ sans mesure de prévention. Le dolasétron et le dropéridol administrés pendant l’opération ont été plus rentables que l’absence de prophylaxie des NVPO chez des patientes subissant une intervention gynécologique ambulatoire. La différence de rentabilité était mince entre les deux médicaments, mais favorisait le dropéridol. C’est un modèle valable pour amener des changements plausibles dans les analyses de sensibilité.


  • Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes

    by Robert M. Balen, Carlo A. Marra, Peter J. Zed, Marc Cohen, Luciana Frighetto


  • Drug and Poison Information Resources on the Internet, Part 2: Identification and Evaluation

    by Carlo A. Marra, Bruce C. Carleton, Larry D. Lynd, Fawziah Marra, Al R. McDougal, Douglas Chow, Ron McKerrow

    The Internet is a potential source of information for practitioners and researchers of pharmaceutical sciences. Despite its explosive growth and popularity, pharmacists and other health care providers have been slow to use the Internet as a source of clinical information. We have identified and evaluated several sites available on the Internet that are devoted to providing information related to professional practice, pharmacotherapy, and toxicology. We have concerns, however, regarding the quality of the available information and advise users to be cautious in using the data they obtain.